Microdose Study Establishes Mass Balance of Elacytarabine - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Microdose Study Establishes Mass Balance of Elacytarabine


Quotient Clinical, a business unit of Quotient Bioresearch, announced the completion of a 14C microdose study with Clavis Pharma, to establish the mass balance of elacytarabine in healthy subjects. The clinical study was an open label, single-dose study to assess the mass balance recovery of an intravenous microdose of 14C-elacytarabine and involved the first dosing of elacytarabine, a cytotoxic molecule, to healthy male subjects.

The study requirement was driven by a request from the US Food and Drug Administration (FDA) to provide information on the routes of elimination of total radioactivity and total recovery.  By performing the study in healthy subjects, Clavis Pharma was able to avoid the complications of extended recruitment periods and potential inconsistency in compliance of a study in patients, according to a company press release.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here